-
Cancer Gene Therapy Market Size to hit $19.97 Billion by 2033 | Key Drivers, Trends, Precision Oncology & FDA
30 Oct 2025 07:32 GMT
… FDA approved a combination therapy of adagrasib and cetuximab … maturing regulatory landscape. Pharmaceutical giants such as Novartis … , and active clinical trials.
Europe (34.5% … science, and biotechnology to redefine oncology treatment. While challenges …
-
Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform
29 Oct 2025 11:33 GMT
… immune response. About Purple Biotech Purple Biotech Ltd. (NASDAQ… 2 study for the treatment of pancreatic ductal adenocarcinoma … and in combination with cetuximab, in which NT219 … Drug Administration or any other applicable regulator of pharmaceutical …
-
Prospects and Challenges of Chitosan-Based Drug Carriers for Anticancer Agents’ Delivery Against Lung Cancer: A Review
24 Oct 2025 14:10 GMT
… of NSCLC cells.71
Medication Delivery Utilizing Active … in cancer diagnosis and treatment. Pharmaceutics. 2023;15(3):1025 … chitosan for cancer nano drug delivery. Biotechnol Adv. 2023;67 … Billa N, Roberts CJ. Cetuximab-conjugated chitosan-pectinate (modified) …
-
Verastem Stock Ignites Retail Buzz After Early Cancer Drug Data Show Tumor Reduction, Mild Side Effects
24 Oct 2025 08:14 GMT
… the drug’s potential for pancreatic and colorectal cancer treatment.
Retail … Medical Officer John Hayslip said the company is encouraged by the drug … ongoing combination trial with cetuximab addresses “a significant unmet need for treatments specifically …
-
NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head and Neck Cancer Trial Sponsorship and Operational Control
24 Oct 2025 06:00 GMT
… biotechnology company pioneering physics-based approaches to expand treatment … States Food and Drug Administration granted regulatory Fast … with or without cetuximab, for the treatment of patients with … (NBTXR3) with Janssen Pharmaceutica NV, a Johnson …
-
Smart Drug Shrinks Tumors in Cancer Patients With No Options Left
22 Oct 2025 19:26 GMT
… in the UK alone. Doctors typically treat the disease … options. The existing treatments, such as cetuximab, have shown limited … are testing this experimental drug, which works in three … 4 trial, presented at the European Society for Medical Oncology …
-
Frontier Medicines Presents Preclinical Data from Three Programs at the 37th AACR-NCI-EORTC International Conference on Molecular Targets
22 Oct 2025 16:05 GMT
… Combination with cetuximab demonstrated more … PROSPER clinical trial (NCT06244771) … Medicines is a clinical-stage precision medicine company pioneering groundbreaking medicines to transform treatment … chemoproteomics-powered drug discovery engine, …
-
Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification
20 Oct 2025 20:00 GMT
… GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company … 2 study for the treatment of pancreatic ductal adenocarcinoma … and in combination with cetuximab, in which NT219 … Drug Administration or any other applicable regulator of pharmaceutical …
-
Advances in the Use of Immune Checkpoint Inhibitors for Colorectal Cancer Treatment
15 Oct 2025 22:15 GMT
… interventional clinical trials were selected … not specify drug targets, 56 … medicine and immunotherapeutic technologies, which have dramatically transformed cancer treatment … cetuximab and irinotecan. Among 33 patients receiving third-line or later treatment …
-
<![CDATA[Navigating Metastatic CRC Treatment Options in Later Lines]]>
10 Oct 2025 22:18 GMT
… , low tumor mutational burden
Medical history: controlled hypertension, type … months of therapy; during treatment patient experienced grade 2 … fluorouracil/irinotecan/cetuximab in second line with initial … : the phase 2 CHRONOS trial. Nat Med. 2022;28 …
About
© 1995-2025